-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Initiates Coverage On CERo Therapeutics Hldgs with Buy Rating, Announces Price Target of $11

Benzinga·04/22/2025 13:59:11
Listen to the news
D. Boral Capital analyst Jason Kolbert initiates coverage on CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy rating and announces Price Target of $11.